Shenep JL, Barton RP, Morgan KA. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. J Infect Dis 1985; 151: 1012–1018.PubMed
Shenep JL, Morgan KA. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis 1984; 150: 380–388.PubMed
Shenep JL, Flynn PM, Barrett FF, Stidham GL, Westenkirchner DF. Serial quantitation of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis. J Infect Dis 1988; 157: 565–568.PubMed
Dunn DL, Mach PA, Condie RM, Cerra FB. Anticore endotoxin F(ab′)2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis. Surg 1984; 96: 440–446.
Dunn DL, Bogard WC, Cerra FB. Efficacy of type-specific and cross reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis. Surg 1985; 98: 283–290.
Adhikari M, Coovadia HM, Gaffin SL, Brock-Utne JG, Marivate M, Pudifin DJ. Septicaemic low birthweight neonates treated with human antibodies to endotoxin. Arch Dis Child 1985; 60: 382–384.PubMed
Morre JN. Endotoxin-induced procoagulant activity, eicosanoid synthesis, and tumor necrosis factor production by rat peritoneal macrophages: effect of endotoxin tolerance and glucan. Circ Shock 1990; 31: 281–295.PubMed
Garner HE, Sprouse RF, Lager K. Cross protection of ponies from sublethalEscherichia coli endotoxemia bySalmonella typhimurium antiserum. Eq Pract 1988; 10: 10–16.
Gaffin SL. Gram-negative bacteraemia: New therapeutic possibilities with anti-endotoxin antibodies. Haematol Blood Trans 1985; 29: 107–111.
Remick DG, Strieter RM, Lynch JP, Nguyen D, Eskandari M, Kunkel SL.In vivo dynamics of murine tumor necrosis factoralpha gene expression: kinetics of dexamethazone-induced suppression. Lab Invest 1991.
Spengler RN, Spengler ML, Strieter RM, Remick DG, Larrick JW, Kunkel SL. Modulation of tumor necrosis factor-alpha gene expression: desensitization of prostaglandin E2-induced suppression. J Immunol 1989; 142: 4346–4350.PubMed
Goto F, Watanabe E, Maruyama N. Prevention of the toxic action of tumor necrosis factor by cyclooxygenase inhibitor and leukopenia. Circ Shock 1989; 29: 175–180.PubMed
White C, Ghezzi P. Protection against pulmonary oxygen toxicity by interleukin-1 and tumor necrosis factor: Role of antioxidant enzymes and effect of cyclooxygenase inhibitors. Biotherapy 1989; 1: 361–367.PubMed
Evans DA, Jacobs DO, Revhaug A. The effects of tumor necrosis factor and their selective inhibition by ibuprofen. Ann Surg 1989; 1: 312–321.
Schade UF, Ernst M, Reinke M. Lipoxygenase inhibitors suppress formation of tumor necrosis factorin vitro
. Biochem Biophys Res Comm 1989; 159: 748–758.PubMed
Sheehan KCF, Ruddle NH, Schreiber RD. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol 1989; 142: 3884–3893.PubMed
Sherry BA, Gelin J, Fong Y. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J 1989; 3: 1956–1962.PubMed
Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990; 172: 599–607.PubMed
Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264: 11974–11980.PubMed
Seckinger P, Isaaz S, Dayer J. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chemistry 1989; 264: 11966–11973.
Dunn DL, Mach PA, Condie RM, Cerra FB. Anticore endotoxin F(ab′)2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial septis. Surg 1984; 96: 440–444.
Miner KM. Characterization of murine monoclonal antibodies toEscherichia coli J5. Infect Immun 1986; 1: 56–62.
Cullor, JS, Fenwick B, Smith BP, Pelzer K, Kelly A, Osbum BI. Active immunization withE. coli J5 and its protective effects from endotoxic shock in calves. In:Immunobiology and Immunopharmacology of Bacterial Endotoxins. Szentivanyi A, Friedman H, Nowotny A, eds. New York, NY: Plenum Press, 1986, p. 265–268.
Walterspiel JW, Kaplan SL, Mason EO. Protective effect of subinhibitory polymyxin-B alone and in combination with ampicillin for overwhelmingHaemophilus infiuenzae Type B infection in the infant rat: Evidence forin vivo andin vitro release of free endotoxin after ampicillin treatment. Ped Res 1986; 20: 237–241.
Bannatyne RM, Cheung R. Infection in neutropenia: Antiendotoxin effect of polymyxin. Anticancer Res 1982; 2: 239–240.PubMed
Cohen J, Pusey CD, Ryan CJ. Protection from endotoxemia: A rat model of plasmaphoresis and specific adsorption with polymyxin-B. J Infect Dis 1987; 155: 690–695.PubMed
Flynn PM, Shenep JL, Stokes DC, Fairclough D, Hildner WK. Polymyxin-B moderates acidosis and hypotension in established experimental gram-negative septicemia. J Infect Dis 1987; 156: 706–712.PubMed
Munster AM, Xiao GX, Guo Y, Wong LA, Winchurch RA. Control of endotoxemiain burn patients by use of polymyxin-B. J Burn Rehab 1989; 10: 327–330.
Hanasawa K. Selective removal of endotoxin from the blood by extracorporeal hemoperfusion with polymyxin B immobilized fiber. Prog Clin Biol Res 1988; 264: 337–341.PubMed
Bannatyne RM, Harnett NM, Lee KY, Biggar WD. Inhibition of the biological effects of endotoxin on neutrophils by polymyxin-B sulfate. J Infect Dis 1977; 136: 469–474.PubMed
Cooperstock M, Riegle L. Polymyxin-B inactivation of lipopolysaccharide in vaccines of gram-negative bacteria. Infect Immun 1984; 33: 315–318.
Corrigan JJ, Bell BM. Comparison between the polymyxins and gentamicin in preventing endotoxin-induced intravascular coagulation and leukopenia. Infect Immun 1971; 4: 563–566.PubMed
Corrigan JJ, Bell BM. Endotoxin-induced intravascular coagulation: prevention with polymyxin-B sulfate. J Lab Clin Med 1971; 77: 802–810.PubMed
Duff GW, Atkin E. The inhibitory effect of polymyxin-B on endotoxin-induced endogenous pyrogens production. J Immunol Methods 1982; 52: 333–340.PubMed
Issekutz AC, Bhimji S, Bartolussi R. Effect of immune serum or polymyxin-B onEscherichia coli
-induced inflammation and vascular injury. Infect Immun 1982; 36: 548–557.PubMed
Luderitz O, Freudenberg MA, Galanos C, Lehman V, Rietschel ET, Shaw DW. Lipopolysaccharides of gramnegative bacteria. In: Current Topics in Membranes and Transport. Bronner F, Kleinzeller A, eds. NY: Academic Press, 1982, p. 79–151.
Sande MA, Mendell GL. Antimicrobial Agents. In: The Pharmacological Basis of Therapeutics. Gilman AG, Goodman LS, Rall TW, Murad F, eds. NY: MacMillan, 1985, p. 1191–1192.
Morrison DC, Jacobs DM. Binding of polymyxin-B to the lipid-A portion of bacterial lipopolysaccharides. Immunochem 1976; 13: 813–818.
Coyne CP, Fenwick BW. Inhibition of lipopolysaccharideinduced macrophage tumor necrosis factor-alpha synthesis by polymyxin-B sulfate. Am J Vet Res 1993; 54: 150–163.
Imoto M, Yshimura N, Kusumoto S. Total synthesis of lipid A, active principal of bacterial endotoxin. Proc J Acad 1984; 60: 285–290.
Hase S, Rietschel ET. Isolation and analysis of the lipid A backbone: Lipid A structure of lipopolysaccharides from various bacterial groups. Eur J Biochem 1973; 63: 101–107.
Stokes D, Shenep JL, Fishman M, Hildner WK, Bysani GK, Rufus K. Polymyxin B prevents lipopolysaccharideinduced release of tumor necrosis factor-alpha from alveolar macrophages. J Infect Dis 1989; 160: 52–57.PubMed
Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibody. Proc Natl Acad Sci 1990; 87: 3127–3131.PubMed
Hohmann HP, Remy R, Brockhaus M, van Loon APGM. Two different cell types have different major receptors for human necrosis factor (TNF-alpha). J Biol Chem 1989; 264: 14927–14934.PubMed
Hohmann HP, Remy R, Poschl B. Tumor necrosis factors-alpha and beta bind to the same two types of tumor necrosis factor receptors and maximally activate the transcription factor NF-kB at low receptor occupancy and within minutes after receptor binding. J Biol Chem 1990; 265: 15183–15188.PubMed
Coyne CP, Fenwick BW, Iandolo J, Griffith G, Williams D. Isolation of an inhibitor of TNF-alpha from activated equine mixed white blood cell populations. Am J Vet Res 1993; 54: in press.
Chia JKS, Pollack M, Guelde G, Koles NL, Miller M, Evans ME. Lipopolysaccharide (LPS)-reactive monoclonalantibodies fail to inhibit LPS-induced tumor necrosis factor secretion by mouse derived macrophages. J Infect Dis 1989; 159: 872–880.PubMed
Han Jf, Thompson P, Beutler B. Dexamethazone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at seperate points in the signaling pathway. J Exp Med 1990; 172: 391–394.PubMed
Taffet SM, Singhel KJ, Overholtzer JF, Shurtleff SA. Regulation of tumor necrosis factor expression in a macrophage like cell line by lipopolysaccharide and cyclic AMP. Cell Immunol 1989; 120: 291–300.PubMed
Meager A, Leung H, Woolley J. Assays for tumour necrosis factor and related cytokines. J Immun Meth 1989; 116: 1–17.
Hofsli EVA, Bakke O, Nonstad U, Espevik T. A flow cytometric and immunofluoroscence microscopic study of tumor necrosis factor production and localization in human monocytes. Cell Immunol 1989; 122: 405–415.PubMed
Espevik T, Nissen-Meyer J. Application of WEHI clone 164 cell line forthe detection of TNF-alpha monokine. J Immunol 1987; 61: 443–449.
Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI clone 164 for measuring cytotoxicity factor/tumor necrosis factor from human monocytes. Methods 1990; 95: 99–105.
Lokesh BR, Sayers TJ, Kinsell JE. Interleukin-1 and tumor necrosis factor synthesis by mouse peritoneal macrophages is enhancedby dietary h-3 polyunsaturated fatty acids. Immunol Let 1990; 23: 281–286.PubMed
Eskandari MK, Nguyen DT, Kinkel SL. WEHI 164 clone 13 assay for TNF: Sensitivity, specificity and reliability. Immunol Invest 1990; 19(1): 69–79.PubMed
Nguyer DT, Eskandari MK, DeForge LE. Cyclosporin-A modulation on tumor necrosis factor gene expression and effectsin vitro andin vivo. Immunol Invest 1990; 144(10): 3822–3828.
Remick DG, Nguyen DT, Eskandari MK. Cyclosporin-A inhibits TNF production without decreasing TNF mRNA levels. Biochem Biophys Res Comm 1990; 161: 551–555.
Hori K, Mihich E, Ehrke MJ. Role of tumor necrosis factor and interleukin-1 in gamma-interferon promoted activation of mouse tumorcidal macrophages. Cancer Res 1989; 49: 2600–2614.
Galanos C, Luderitz O, Rietschel ET, Westphal O. Newer aspects of the chemistry and biology of bacterial lipopolysaccharides, with special reference to their lipid-A components. In: Intern Rev of Biochem Biochemistry of Lipids II, Goodwin, TW, ed. Baltimore: Univ Park Press, 1977, p. 239–335.
Rietschel ET, Hase S, King MT. Chemical structure of lipid A. Eur J Biochem 1976; 63: 262–268.
Westphal O, Gmeiner J, Luderitz O. Chemistry and biology of the lipid-A component of enterobacterial lipopolysaccharides. Colloq Int CNRS Paris 1969; 174: 69–78.
Rifkind D. Prevention by polymyxin-B of endotoxin lethality in mice. J Bacteriol 1967; 93: 1463–1464.PubMed
Corrigan JJ, Sieber OF, Ratajczak H, Bennet BB. Modification of human neutrophil response to endotoxin with polymyxin-B sulfate. J Infect Dis 1974; 130: 384–387.PubMed
Cooperstock MS. Inactivation of endotoxin by polymyxin-B. Antimicrob Agents Chemother 1974; 6: 422–425.PubMed
Craig WA, Turner JH, Kunin CM. Prevention of the generalized Schwartzman reaction and endotoxin lethality by polymyxin-B localized in tissues. Infect Immun 1974; 10: 287–292.PubMed
Palmer JD, Rifkind D. Neutralization of the hemodynamic effects of endotoxin by polymyxin-B. Surg Gynecol Obstet 1974; 138: 755–759.PubMed
Fong JSC, Good RA. Polymyxin-B sulfate modification of bacterial endotoxin: effects on the development of endotoxic shock in dogs. Infect Immun 1979; 23: 660–664.PubMed
Coopershock M, Riegle L. Polymyxin-B inactivation of lipopolysaccharide in vaccines of gram-negative bacteria. Infect Immun 1981; 33: 315–318.PubMed
Hughes B, Riegle L. Polymyxin-B sulfate protects cats against the haemodynamic and metabolic effects ofE. coli
endotoxin. Br J Pharmacol 1981; 74: 701–707.PubMed
Rudd P, Blaschke T. Antihypertensive agents and the drug therapy of hypertension. In: The Pharmacological Basis of Therapeutics. Gillman AG, Goodman LS, Rall TW, Murad F, eds. NY: MacMillan, 1985, p. 784–805.
Rifkind D, Palmer JD. Neutralization of endotoxin toxicity in chick embryos by antibiotics. J Bacteriol 1966; 92: 815–819.PubMed
Takayama K, Qureshi N, Raetz CRH,et al
. Influence of fine structure of lipid-A on Limulus amebocyte lysate clotting and toxic activities. Infect Immun 1984; 45: 350–355.PubMed
Takayama K, Qureshi N, Ribi E, Cantrell JL, Amano K. Use of endotoxin in cancer immunotherapy and characterization of its nontoxic but active lipid-A components. In: Bacterial Lipopolysaccharides: Structure, Synthesis, and Biological Activities, Anderson L, Unger F, eds. Washington. D.C.: American Chemical Society, 1983, p. 219–233.
Endres S.in vitro
production of IL-1 beta, IL-2 alpha, TNF and IL-2 in healthy subjects, distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol 1989; 19: 2327–2333.PubMed
Suffys P, Beyoert R, Van Roy F, Fiers W. Reduced tumor necrosis factor-induced cytotoxicity by inhibitors of the arachidonic acid metabolism. Biochem Biophys Res Commun 1987; 149: 735–743.PubMed
Fleisher LN. Time course for prostaglandin synthesis by rabbit lens during endotoxin-induced ocular inflammation. Curr Eye Res 1986; 5: 629–634.PubMed
Suttorp N. Endotoxin alters arachidonate metabolism in pulmonary endothelial cells. Am J Physiol 1987; 253: 383-C390.
Zia S, Giri SN, Cullor GJ, Emau P, Osburn BI, Bushnell. Role of eicosanoid, histamine, and serotonin in the pathogenisis of Klebsiella pneumonia-induced bovine mastitis. Am J Vet Res 1987; 48: 1617–1625.PubMed
Giri SN, Chen Z, Carroll EJ,et al
. Role of prostaglandins in pathogenisis of bovine mastitis induced byEscherichia coli
endotoxin. Am J Vet Res 1984; 45: 586–591.PubMed
Schneider J. Effects of recombinant human Superoxide dismutase on increased lung vascular permeability and respiratory disorder in endotoxic rats. Circ Shock 1990; 30: 97–106.PubMed
Recasens JF. Effects of endotoxin and anti-inflammatory agents on Superoxide dismutase in the rabbit iris. Ophthalmic Res 1990; 22: 12–18.PubMed
Cerasoli F. Superoxide anion release from blood and bone marrow neutrophils is altered by endotoxemia. Circ Res 1990; 67: 154–165.PubMed
Schade UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Cir Shock 1990; 31: 171–181.
Exley AR. Monoclonal antibody to TNF in severe septic shock. Lancet 1990; 335: 1275–1277.
Schollmeier K. Immunologic and pathophysiologic role of tumor necrosis factor. Am J Respir Cell Mol Biol 1990; 311: 11–12.
Silva AT. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock. J Inf Dis 1990; 162: 421–427.
Bonavida B. The involvement of platelet-activating factor (PAF)-induced monocyte activation and tumor necrosis factor (TNF) production in shock. Prog Clin Biol Res 1989; 308: 485–489.PubMed
Fong Y, Lowry SF. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immun Immunopath 990; 1 55: 157–170.
Hinshaw LB, Tekamp-Olson P, Chang ACK. Survival of primates in LD-100 septic shock following therapy with antibody to tumor necrosis factor (TNF-alpha). Circ Shock 1990; 30: 279–292.PubMed
Leon P. Interleukin-1 and its relationship to endotoxin tolerance. Arch Surg 1992; 127: 146–151.PubMed
Montz H. The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1. Immunol 1991; 74: 373–379.
Wang MH. Inhibition of endotoxin-induced interleukin-6 production by synthetic lipid-A partial structures in human peripheral blood mononuclear cell. Infect Immun 1991; 59: 4655–4664.PubMed
The Swiss Dutch J5 Immunoglobulin Study Group. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1991; 99: 23–29.
Semenzato G. Tumor necrosis factor: a cytokine with multiple biological activities. Br J Cancer 1990; 61: 354–361.PubMed
Remick DG, Strieter RM, Eskandari MK,et al
. Role of tumor necrosis factor-alpha in lipopolysaccharide-induced pathologic alterations. Amer J Path 1990; 136: 49–60.PubMed
Remick DG, Kunkel RG, Larrick JW, Kunkel SL. Acutein vivo
effects of human recombinant tumor necrosis factor. Lab Invest 1987; 56: 583–590.PubMed
Tracy KJ, Beutler B, Lowry SF. Shock and tissue injury induced by recombinant human cachectin. Sci 1986; 470: 234–238.
Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81: 1925–1937.PubMed
Kawasaki H, Moriyama M, Ohtani Y, Naitoh M, Tanaka A, Nariuchi H. Analysis of endotoxin fever in rabbits by using a monoclonal antibody to tumor necrosis factor (cachectin). Infect Immun 1989; 57: 3131–3135.PubMed
Silva AT, Bayston KF, Cohen J. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factoralpha in experimental gram-negative shock. J Infect Dis 1990; 162: 421–427.PubMed
de Groote MA, Martin MA, Densen P, Pfaller MA, Wenzel RP. Plasma tumor necrosis factor levels in patients with presumed sepsis. JAMA 1989; 262: 249–251.PubMed
Sanchez-Cantu L. Endotoxin tolerance is associated with reduced secretion of tumor necrosis factor. Arch Surg 1989; 124: 1432–1435.PubMed
Poll T. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622–1627.PubMed
Myers AK. Relationships between tumor necrosis factor, eicosanoids and platelet activating factor as mediators of endotoxin-induced shock in mice. Br J Pharmacol 1990; 99: 499–502.PubMed
Flynn PM, Shenep JL, Stokes DC, Fairclough D, Hildner WK. Polymyxin-G moderates acidosis and hypotension in established, experimental gram-negative septicemia. J Infect Dis 1987; 156: 706–712.PubMed
Yow EM, Moyer JH. Toxicity of polymyxin B. II. Human studies with particular reference to evaluation of renal function. Arch Int Med 1953; 92: 248–257.
Danner RL, Joiner KA, Rubin M,et al
. Purification, toxicity, and antiendotoxin activity of polymyxin-B nonapeptide. Antimicrob Agents Chemother 1989; 33: 1428–1434.PubMed